So that’s a really good question. I think it’s evolving, and my hope is it’s evolving towards potentially a new treatment option for select patients. So I think what was I think most remarkable is that this study, which was sponsored by Iovance, did serve as a foundation for the development design of a phase two trial sponsored by Iovance that’s now open, called SARATOGA , across multiple U...
So that’s a really good question. I think it’s evolving, and my hope is it’s evolving towards potentially a new treatment option for select patients. So I think what was I think most remarkable is that this study, which was sponsored by Iovance, did serve as a foundation for the development design of a phase two trial sponsored by Iovance that’s now open, called SARATOGA , across multiple U.S. centers, including MSK. And so that trial is now designed to interrogate the efficacy with that in mind. And specifically asking that question is that signal that we saw going to pan out when we think about this as this as a treatment option for our patients and so my hope is that it’s moving and evolving towards you know on that route right it’s a hard regulatory pathway especially in a rare disease and our trials are smaller and so we have a little bit of a hill to climb but my hope is we’ll get there
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.